Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Krystal Biotech (KRYS) EBIAT (2021 - 2025)

Krystal Biotech's EBIAT history spans 5 years, with the latest figure at $51.4 million for Q4 2025.

  • For Q4 2025, EBIAT rose 13.02% year-over-year to $51.4 million; the TTM value through Dec 2025 reached $204.8 million, up 129.74%, while the annual FY2025 figure was $204.8 million, 129.74% up from the prior year.
  • EBIAT for Q4 2025 was $51.4 million at Krystal Biotech, down from $79.4 million in the prior quarter.
  • Across five years, EBIAT topped out at $80.7 million in Q3 2023 and bottomed at -$50.0 million in Q1 2022.
  • The 5-year median for EBIAT is -$7.3 million (2021), against an average of $4.8 million.
  • The largest annual shift saw EBIAT tumbled 215.99% in 2022 before it skyrocketed 3734.01% in 2025.
  • A 5-year view of EBIAT shows it stood at -$21.8 million in 2021, then tumbled by 46.99% to -$32.1 million in 2022, then skyrocketed by 127.12% to $8.7 million in 2023, then soared by 423.23% to $45.5 million in 2024, then grew by 13.02% to $51.4 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's EBIAT are $51.4 million (Q4 2025), $79.4 million (Q3 2025), and $38.3 million (Q2 2025).